# A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

> **NCT04707079** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT04707079
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-18
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707079, "A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04707079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*